The forecast for non-steroid anti-inflammatory and antirheumatic medicine sales in Canada shows a gradual decline from 2024 to 2028, from CAD 295.6 million to CAD 288.1 million. As compared to actual data from 2023, the year-on-year percentage variations indicate a slight decrease. The compound annual growth rate (CAGR) over this five-year forecast period suggests a small negative trend, reflecting a contraction in sales.

Future trends to watch for include:

Innovation in drug formulations or treatment methods may impact these forecasts.
Changes in regulatory policies affecting medication pricing and availability could alter sales projections.
Population demographics, such as an aging population, may affect demand dynamics.